Dermatology online journal最新文献

{"title":"Primary cutaneous coccidioidomycosis.","authors":"Simran D Bhakta, Ashley S Parker, Manuela Lori Asztalos","doi":"10.25251/r765s2a7","DOIUrl":"https://doi.org/10.25251/r765s2a7","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocutaneous sporotrichosis with osteoarticular involvement.","authors":"Sabrina G Silva, Bianca B F Villar, Laura C Ferreira, Remberto Maurício C V Vilte, Billy McBenedict, Natalia C Z Silva, Karla R O M Ronchini, Bruno C Fonseca, Patricia Y M Pinheiro, Ezequias B Martins","doi":"10.25251/itpsd64i","DOIUrl":"https://doi.org/10.25251/itpsd64i","url":null,"abstract":"","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sport-related skin conditions: Traumatic and inflammatory dermatoses.","authors":"Joshua Burshtein, Stephen Donohue, Darrell S Rigel","doi":"10.25251/4ezdc4g6","DOIUrl":"10.25251/4ezdc4g6","url":null,"abstract":"<p><strong>Background: </strong>Athletes are at risk of developing dermatologic conditions, particularly traumatic and inflammatory dermatoses, owing to the physical and environmental stresses associated with sports participation. As sports participation continues to increase worldwide, recognition of these conditions has become increasingly important for dermatologists and sports medicine professionals.</p><p><strong>Objective: </strong>To review the epidemiology, clinical presentations, prevention strategies, and treatment approaches for common traumatic and inflammatory dermatoses encountered in athletes.</p><p><strong>Methods: </strong>A comprehensive literature search was completed using a combination of keywords: \"sports,\" \"traumatic,\" \"inflammatory,\" \"skin,\" and \"dermatoses.\" The authors reviewed all studies and included those that addressed the topic of the review.</p><p><strong>Results: </strong>Traumatic dermatoses represented the most frequently reported conditions. Inflammatory dermatoses primarily included contact dermatitis and lichen simplex chronicus. Many conditions demonstrate sport-specific patterns related to repetitive friction, pressure, direct trauma, moisture, or exposure to athletic equipment. Preventive measures include proper equipment fit, reduction of friction and moisture, and use of protective barriers, while treatment strategies ranged from wound care and topical therapies to procedural interventions.</p><p><strong>Conclusion: </strong>Sports participation is associated with a broad spectrum of traumatic and inflammatory skin disorders that may affect athlete comfort, performance, and participation.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the safety of dermatological and surgical procedures in patients undergoing systemic isotretinoin therapy: An updated review.","authors":"Helana Ghali, Abigail Nunez, Kate Beekman, Alison H Kucharik, Lilia Correa-Selm, Sharon E Albers","doi":"10.25251/8qrq7122","DOIUrl":"10.25251/8qrq7122","url":null,"abstract":"<p><strong>Background: </strong>Isotretinoin is a highly effective treatment for severe nodulocystic acne. Concerns regarding impaired wound healing and an increased risk of hypertrophic or keloid scarring have historically led to recommendations that cutaneous procedures be delayed for at least 6 months after isotretinoin therapy. Recent evidence has challenged the necessity of this practice.</p><p><strong>Objective: </strong>To review the current literature evaluating the effects of isotretinoin on skin and wound healing in patients undergoing dermatologic, cosmetic, and surgical procedures.</p><p><strong>Methods: </strong>A comprehensive review of published studies examining wound healing outcomes, scarring, and procedural complications in patients receiving concurrent or recent isotretinoin therapy was performed. Evidence was evaluated across multiple procedure categories, including dermabrasion, laser treatments, chemical peels, microneedling, cutaneous surgery, ophthalmic surgery, and other surgical interventions.</p><p><strong>Results: </strong>Most contemporary studies reported normal wound healing and a low incidence of adverse scarring in patients undergoing procedures during or shortly after isotretinoin treatment. Evidence supporting a mandatory 6-month discontinuation period was limited and was largely based on older case reports and small case series. Studies evaluating laser therapies, chemical peels, microneedling, and various surgical procedures generally demonstrated favorable outcomes without increased rates of hypertrophic scarring or keloid formation. Several investigations also reported improved acne severity, acne scarring, and patient satisfaction when isotretinoin was combined with procedural interventions.</p><p><strong>Conclusion: </strong>Current evidence suggests that the risk of abnormal wound healing or scarring associated with concurrent or recent isotretinoin use is minimal for most dermatologic and surgical procedures. Routine postponement of procedures solely because of isotretinoin therapy may be unnecessary in many patients. Further prospective studies, particularly in individuals with darker skin phototypes and those predisposed to abnormal scar formation, are needed to refine clinical recommendations.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome dysbiosis in psoriatic skin among Asian populations: Insights from a systematic review and meta-analysis.","authors":"Salman Khan, Danyal Hussain, Haris Ahmad, Sharjeel Ahmed","doi":"10.25251/fpzgo476","DOIUrl":"10.25251/fpzgo476","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic immune-mediated skin disease increasingly associated with microbial dysbiosis.</p><p><strong>Objective: </strong>To clarify patterns of skin microbiome alteration in psoriasis.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of Asian cohort studies. Eleven studies were included.</p><p><strong>Results: </strong>Results for α-diversity were inconsistent, with Shannon and Simpson indices showing heterogeneous outcomes. In contrast, genus-level analysis revealed consistent taxonomic trends: psoriatic lesions demonstrated enrichment of <i>Staphylococcus</i> and <i>Streptococcus</i> with concurrent depletion of <i>Cutibacterium</i>. Fungal analyses showed redistribution of <i>Malassezia</i> species, with increased burden reported in Japanese, Chinese, and Iranian cohorts. Funnel plots indicated limited publication bias, and sensitivity analyses confirmed that exclusion of therapeutic cohorts did not alter results. Importantly, IL-17A inhibitor studies demonstrated partial restoration of microbial balance following treatment. These findings provide reproducible evidence of microbiome shifts in psoriatic skin across Asian populations. The results suggest that specific bacterial and fungal taxa may serve as biomarkers of disease activity and therapeutic response.</p><p><strong>Conclusion: </strong>Future mechanistic work should integrate microbiome and host immune pathways to advance development of microbiome-targeted interventions in psoriasis.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnesium dysregulation and risk of inflammatory skin disease: A multicenter cohort study.","authors":"Natalia Chalupczak, Alexa S Podolsky, Shari R Lipner","doi":"10.25251/nnzpm9sp","DOIUrl":"10.25251/nnzpm9sp","url":null,"abstract":"<p><strong>Background: </strong>Magnesium is essential for epidermal differentiation and immune regulation and dysregulated magnesium homeostasis has been implicated in chronic inflammation. However, its association with inflammatory skin diseases has been poorly characterized.</p><p><strong>Objective: </strong>To investigate whether abnormal serum magnesium levels are associated with increased risk of psoriasis, atopic dermatitis, and acne in a real world population.</p><p><strong>Methods: </strong>Using the TriNetX multicenter database, adults aged 18-65 years with hypomagnesemia (serum magnesium 0.0-1.6 mg/dL) or hypermagnesemia (≥2.6 mg/dL) were identified on November 12, 2025 (query range 2008-2025) and propensity score matched 1:1 to controls with normal magnesium levels. Matching variables included age, sex, race, ethnicity, chronic kidney disease (stages 1-5), bariatric surgery, and alcohol related disorders. Risk ratios (RR) and odds ratios with 95% confidence intervals (CIs) were calculated using logistic regression. Significance was set at p<0.05.</p><p><strong>Results: </strong>After matching, 246,648 patients with hypomagnesemia and 86,649 patients with hypermagnesemia, as well as respective controls were included. Hypomagnesemia was associated with significantly increased risk of psoriasis (RR 1.173; 95% CI 1.098-1.253; p<0.0001) and atopic dermatitis (RR 1.091; 95% CI 1.027-1.160; p=0.0051), but not acne (RR 0.971; 95% CI 0.931-1.014; p=0.1843). Hypermagnesemia was not significantly associated with psoriasis, atopic dermatitis, or acne (all p≥0.05).</p><p><strong>Conclusion: </strong>Hypomagnesemia, but not hypermagnesemia, was associated with increased risk of psoriasis and atopic dermatitis. These findings suggest a potential role for magnesium deficiency in cutaneous inflammatory pathogenesis and warrant further mechanistic and longitudinal studies.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns for bullous pemphigoid in older adults: A population-based study.","authors":"Abigail Katz, Hannah C Tolson, Julian A Cortes, Alyssa M Roberts, Yvonne Nong, Charlotte Y Jeong, Elaine Ma, Peichi Chou, Matthew J Yan, Nicole Johnsen, Camila Carranza, Vanessa R Holland, Yusuke Tsugawa, April W Armstrong","doi":"10.25251/cwvjt950","DOIUrl":"10.25251/cwvjt950","url":null,"abstract":"<p><strong>Background: </strong>Bullous pemphigoid (BP) is a chronic autoimmune blistering disease that disproportionately affects older adults and is associated with substantial morbidity, mortality, and treatment-related risks. Despite an expanding therapeutic landscape, real-world prescribing patterns in this population remain poorly characterized.</p><p><strong>Objective: </strong>To evaluate medication prescribing patterns among older adults with BP and assess the feasibility of using national claims data to characterize treatment exposures relevant to drug safety and risk stratification.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using Medicare fee-for-service claims data (2016-2020). Adults aged 65 years or older with BP were identified using ICD-10 codes. Prescription drug event data were linked to outpatient claims to capture medication use. Treatments were categorized into topical corticosteroids (by potency), oral immunomodulators and antibiotics, and biologic therapies. Descriptive analyses were performed to evaluate prescribing distributions.</p><p><strong>Results: </strong>Among 10,959 patients with BP and 78,468 outpatient claims, we identified 19,663 prescriptions. Oral immunomodulators and antibiotics comprised 67.5% of prescriptions, followed by topical corticosteroids (32.5%) and biologics (0.04%). Prednisone accounted for 62.9% of oral prescriptions, followed by doxycycline (20.2%) and mycophenolate (6.0%). Among topical steroids, medium-potency agents were most common (40.6%), followed by super high-potency (38.2%). Biologic use was rare, with dupilumab accounting for most prescriptions.</p><p><strong>Conclusion: </strong>Systemic corticosteroids remain the predominant therapy for BP in older adults, with substantial variability in topical steroid use and minimal uptake of biologics. These findings highlight gaps in treatment optimization and support the need for risk-informed, steroid-sparing strategies in this high-risk population.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapies against type I interferon and TNF-alpha in cutaneous lupus erythematosus: A systematic review of randomized trials.","authors":"Daniela Andrea Candia González, Daniela Dávila Vargas, Verónica Arango Machado, Valentina Araque Díaz, Juan Pablo Alzate Granado, Francisco Javier Gómez Ballesta","doi":"10.25251/mgn4rt3l","DOIUrl":"10.25251/mgn4rt3l","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous lupus erythematosus (CLE) is associated with high symptomatic burden and sustained activation of immune pathways, notably type I interferon (IFN-I) and tumor necrosis factor-alpha (TNF-α). In patients refractory to standard treatments, such as photoprotection, corticosteroids, antimalarials, and immunomodulators, targeted therapies have emerged as potential alternatives.</p><p><strong>Objective: </strong>To assess the efficacy and safety of targeted therapies against IFN-I or TNF-α compared to standard treatments in patients with CLE.</p><p><strong>Methods: </strong>A systematic review was conducted of randomized controlled trials (RCTs) involving adults or adolescents with CLE (with or without systemic lupus erythematosus), reporting cutaneous outcomes (CLASI-A, CLASI-50, responder rates) and safety. Literature searches were performed in MEDLINE, Embase, and LILACS without language restrictions. Risk of bias was evaluated using the Cochrane RoB 2 tool. Owing to clinical heterogeneity, results were synthesized narratively.</p><p><strong>Results: </strong>Eight RCTs met inclusion criteria, predominantly evaluating IFN-I pathway inhibitors. Anifrolumab showed significant benefit in TULIP-2 (CLASI-50: 49% vs 25%; P = .001) and MUSE (63% vs 30.8%). Sifalimumab achieved CLASI-50 responses up to 73%. Deucravacitinib (TYK2 inhibitor) and BIIB059 (anti-BDCA2) also showed clinical improvements. RSLV-132 and epratuzumab did not demonstrate efficacy. IFN-I blockade was associated with increased viral infections, particularly herpes zoster. Two studies were rated as high risk of bias; the remainder presented some concerns.</p><p><strong>Conclusion: </strong>Targeted inhibition of IFN-I and TYK2 pathways appears effective in reducing cutaneous activity in CLE, with acceptable safety profiles. Evidence for anti-TNF therapies remains insufficient. Further trials stratified by CLE subtype and patient-reported outcomes are warranted to inform clinical guidelines.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-reported factors influencing adherence to oral psoriasis treatment.","authors":"Brett R Shaffer, Katie K Lovell, Jonathan D Greenzaid, Mallory Zaino, Vani Subramanian, Deepak Sirdeshmukh, Nestor Wiegandt, Irma Richardson, Steven R Feldman","doi":"10.25251/i71hs71j","DOIUrl":"10.25251/i71hs71j","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis impairs quality of life, and treatment efficacy is limited by poor adherence. Although patients prefer oral therapies, adherence to oral medications can also be low.</p><p><strong>Objective: </strong>To examine factors influencing adherence to deucravacitinib, an oral selective tyrosine kinase 2 inhibitor.</p><p><strong>Methods: </strong>Forty adults with plaque psoriasis were provided deucravacitinib 6 mg daily and an electronic monitoring dock that recorded dose events. Participants were randomized to standard monitoring or monitoring with electronic reminders. After study completion, participants were stratified into the most (top 20%, T20) and least (bottom 20%, B20) adherent groups. Short-answer qualitative interviews were conducted at study conclusion, and responses were grouped into themes based on content analysis.</p><p><strong>Results: </strong>Twenty-eight participants completed the study. Mean adherence was 98.6% ± 0.9% in T20 (n = 13) and 82.5% ± 10.7% in B20 (n = 6). All participants self-reported taking the medication as prescribed. The T20 participants reported understanding how deucravacitinib works and cited electronic reminders as helpful for adherence. The B20 most frequently relied on routine to help with adherence.</p><p><strong>Conclusion: </strong>Greater understanding of therapy and use of reminders were associated with higher adherence. Patients relying on routine may benefit from structured reminder systems.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatomyositis: Dermoscopic features and a short review.","authors":"Fatima-Ezzahraa Zeroual, Layla Bendaoud, Maryam Aboudourib, Ouafa Hocar, Said Amal","doi":"10.25251/2wyrnt94","DOIUrl":"10.25251/2wyrnt94","url":null,"abstract":"<p><strong>Background: </strong>Dermoscopy has demonstrated utility in several connective tissue diseases. However, in dermatomyositis, it has been poorly studied for both cutaneous and nailfold involvement.</p><p><strong>Results: </strong>We report the cutaneous and nailfold dermoscopic features in 11 patients with dermatomyositis and compare them with previously published data.</p><p><strong>Methods: </strong>Key cutaneous findings included linear vessels with a uniform distribution, white scales observed in all 11 patients, structureless white areas in 9 patients, brown globules in 9 patients, and mottled brown pigmentation in 8 patients. Nailfold dermoscopy revealed dilated capillaries and avascular areas in all patients, architectural disorganization in 10 patients, tortuous vessels in 8 patients, hemorrhages in 7 patients, and megacapillaries in 2 patients. Few studies have described dermoscopic features in dermatomyositis, some of them being isolated case reports with incomplete and heterogeneous clinical data. The largest published series included 29 patients and described polymorphic cutaneous vascular patterns, predominantly sparse white scales, as well as nailfold megacapillaries and dilated capillaries, without reporting follicular structures, shapes, or colors.</p><p><strong>Conclusion: </strong>Larger studies are needed to more precisely identify the distinctive dermoscopic signs of dermatomyositis and to evaluate the potential of dermoscopy as a prognostic tool for disease activity and progression.</p>","PeriodicalId":11040,"journal":{"name":"Dermatology online journal","volume":"32 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}